Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
November 26 2021 - 6:10AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
November 26, 2021
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F [X]
|
Form 40-F [ ]
|
Indicate by check mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g-32(b):82-________
Novo
Nordisk announces impact from Volume Based Procurement for insulin in China
Bagsværd, Denmark, 26 November
2021 – Novo Nordisk today announced that the company has received the results from the Volume Based Procurement (VBP) tender
for insulin in China. The Chinese National Healthcare Security Administration has tendered insulin sold at hospitals, and Novo Nordisk
has participated in the tender. All Novo Nordisk’s insulin were included in the tender except for Ryzodeg®
and Xultophy®.
Novo Nordisk currently expects an estimated negative impact on
global sales growth of around 3% in 2022 as a result of reduced prices and reduced volumes of insulin sold in China. The VBP for insulin
is expected to be implemented during the first half of 2022.
Novo Nordisk will provide the financial outlook for 2022 in connection
with the announcement of the full-year 2021 results on 2 February 2022.
About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded
in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity
and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working
to prevent and ultimately cure disease. Novo Nordisk employs about 47,000 people in 80 countries and markets its products in around 170
countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).
Page 2 of 2
Further information
Media:
|
|
|
Mette Kruse Danielsen
|
+45 3079 3883
|
mkd@novonordisk.com
|
Michael Bachner (US)
|
+1 609 664 7308
|
mzyb@novonordisk.com
|
Investors:
|
|
|
Daniel Muusmann Bohsen
|
+45 3075 2175
|
dabo@novonordisk.com
|
Ann Søndermølle Rendbæk
|
+45 3075 2253
|
arnd@novonordisk.com
|
David Heiberg Landsted
|
+45 3077 6915
|
dhel@novonordisk.com
|
Mark Joseph Root (US)
|
+1 848 213 3219
|
mjhr@novonordisk.com
|
Novo Nordisk A/S
Investor Relations
|
Novo Allé
2880 Bagsværd
Denmark
|
Telephone:
+45 4444 8888
|
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
|
|
|
Company announcement No 74/ 2021
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: November 26, 2021
|
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer
|
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Jul 2023 to Jul 2024